On Friday, Pfizer presented the first results in humans for its gene therapy to treat Duchenne muscular dystrophy. Pfizer shares were flat on the announcement, but shares in Sarepta Therapeutics, which is developing its own treatment, increased 18%. STAT senior writers Adam Feuerstein and Matthew Herper sat down with some highly caffeinated beverages this morning to discuss the results.

Adam: Hey, Matt, the consensus seems to be that Sarepta Therapeutics has a more effective and safer gene therapy than Pfizer. That’s the big takeaway from the Pfizer presentation on Friday. How do you feel about that?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi Matt,
    I think your comment that Pfizer deserves to be criticized for using a ‘new’ dystrophin detection assay is misplaced. First, it isn’t that new (first presented 2-3 years ago), it is a significant advance in measuring dystrophin (greater sensitivity, much wider dynamic range), and according to the slides Pfizer presented, the FDA reviewed it and gave a thumbs up.
    It is not unprecedented for an LCMS method to became the new gold standard.
    Best, S

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy